# ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
Canonical URL: https://biopharmsignal.com/news/PLSE/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million
Ticker: PLSE
Company: Pulse Biosciences
Source: Pulse Biosciences
Published: 2026-05-12 11:00 EST
Original Source URL: https://investors.pulsebiosciences.com
## Summary

HAYWARD, Calif. --(BUSINESS WIRE)--May 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette,

## Article Body
HAYWARD, Calif. --(BUSINESS WIRE)--May 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette,
## Recent Company News
- 2026-05-27 20:05 EST — [Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Pulse Biosciences
- 2026-05-12 11:00 EST — [ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million](https://biopharmsignal.com/news/PLSE/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million) — Source: Pulse Biosciences
- 2026-05-08 11:00 EST — [Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference) — Source: Pulse Biosciences
- 2026-05-04 11:00 EST — [Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLSE/pulse-biosciences-reports-business-updates-and-first-quarter-2026-financial-results) — Source: Pulse Biosciences
- 2026-04-25 17:00 EST — [Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-presents-positive-outcomes-in-late-breaking-updated-data-from-npulsetm-cardiac-catheter-system-at-heart-rhythm-2026) — Source: Pulse Biosciences
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)